The purpose of this study is to assess the safety and efficacy of MDMA-Assisted Therapy on Frontline Health Care Workers and First Responders suffering from symptoms of Post-Traumatic Stress.

Start Date01 Oct 2026

Sponsor / Collaborator

Nautilus Sanctuary

NCT07569159

/ Not yet recruitingPhase 2

A Phase 2, Open-Label Study Investigating the Safety and Efficacy of MDMA-Assisted Therapy for Veterans With Posttraumatic Stress Disorder (PTSD)

A Phase 2, single-center, fixed-dose, open-label study will explore the efficacy, safety, and tolerability of a 120 mg dose of oral MDMA followed by a supplemental dose of 60 mg MDMA in conjunction with therapy in individual versus group settings for adult veterans diagnosed with PTSD.

Start Date01 Jul 2026

Sponsor / Collaborator

Sunstone Medical LLC

NCT07288151

/ RecruitingPhase 2IIT

MDMA-Assisted Massed Exposure Therapy for PTSD

The goal of this clinical trial is to investigate the efficacy of 3,4-methylenedioxy-methamphetamine hydrochloride (MDMA) combined with Massed Prolonged Exposure (PE) therapy for the treatment of posttraumatic stress disorder (PTSD) in adult participants diagnosed with PTSD. This randomized, placebo-controlled trial will enroll 95 participants.
The main questions it aims to answer are:
* Does the combination of PE + MDMA lead to greater reduction in PTSD symptom severity from pre-treatment to one-month follow-up compared to PE + placebo?
* Does PE + MDMA improve response efficiency and durability of PTSD symptom improvement compared to PE + placebo?
* Does MDMA + PE enhance extinction retention and reduce amygdala threat reactivity, and are these changes associated with improved PTSD outcomes?
Participants will:
* Receive 10 sessions of Massed Prolonged Exposure therapy over two weeks
* Be administered either 100 mg of MDMA or a placebo at Visit 2
* Undergo blinded independent evaluator assessments using the Clinician-Administered PTSD Scale for DSM-5-R (CAPS-5-R) at the one-month posttreatment follow-up

Start Date01 Jul 2026

Sponsor / Collaborator

Emory University

100 Clinical Results associated with Methylenedioxymetamfetamine

100 Translational Medicine associated with Methylenedioxymetamfetamine

100 Patents (Medical) associated with Methylenedioxymetamfetamine

6,934

Literatures (Medical) associated with Methylenedioxymetamfetamine

31 Dec 2026·European Journal of Psychotraumatology

The microbiome and PTSD: a scoping review across preclinical and clinical studies

Review

Author: Hemmings, Sian ; Lindauer, Ramon ; Korosi, Aniko ; Verkleij, Marieke ; Lok, Anja ; Berendse, Ronja ; Zantvoord, Jasper B ; Daams, Joost

BACKGROUND:

Posttraumatic Stress Disorder (PTSD) is a psychiatric condition that substantially impairs quality of life and global health. Emerging evidence implicates that the human microbiome contributes to PTSD pathophysiology via gut-brain-immune interactions, although the underlying mechanisms and therapeutic implications remain unclear.

OBJECTIVE:

This review aimed to systematically map the evidence linking microbiome alterations to PTSD, with a focus on mechanistic pathways, therapeutic potential, and research gaps.

METHODS:

This scoping review was conducted in Medline, Embase, and PsychINFO from inception to 18-03-2025. Eligible studies included human participants with PTSD and preclinical rodent models employing validated PTSD paradigms. Outcomes of interest included microbiome diversity and composition, gut-brain axis biomarkers, and effects of microbiome-targeted interventions.

RESULTS:

Fifty studies were included, comprising 20 human, 29 preclinical and one cross-species study. Human observational studies frequently observed reduced overall microbial diversity, along with a loss of short-chain fatty acid (SCFA)-producing bacteria, such as Ruminococcaceae and Lachnospiraceae, and an increased abundance of Veillonella, Odoribacter, and Catenibacterium linked to gut permeability and inflammation. Human intervention studies testing probiotics, prebiotics, fermented soy, and dietary fibre showed preliminary evidence for symptom and related metabolic and inflammatory marker improvements; however, microbiome effects were inconsistent. Preclinical models revealed stress-induced reductions in Bifidobacteria, Verrucomicrobia, and Parabacteroides, and increases in Coprobacillus and Anaeroplasma. Functional consequences included impaired barrier integrity, altered SCFA levels, and heightened immune activation. Preclinical interventions, particularly Mycobacterium vaccae, as well as probiotics, synbiotics, acetate, and MDMA, mitigated microbial alterations, reduced anxiety-like behaviours, and modulated neuroimmune pathways.

CONCLUSION:

Current evidence supports an association between PTSD and microbiome alterations, with convergent human and preclinical findings. However, human research remains limited by small, cross-sectional designs, which preclude causal inferences. Rigorous longitudinal and interventional studies are required to establish causality and assess microbiome-targeted therapies as adjuncts in PTSD treatment.

31 Dec 2026·European Journal of Psychotraumatology

A neurocognitive account of complex PTSD: self-modelling, affective dysregulation, and implications for MDMA-assisted and targeted psychotherapies

Review

Author: Gerrans, Philip ; Hohwy, Jakob ; Oestreich, Lena K L ; Mcgovern, Hugh

Background: Complex post-traumatic stress disorder (C-PTSD) is a trauma-related condition characterized by pervasive disturbances in affect regulation, self-concept, and interpersonal functioning that extend beyond the symptom profile of post-traumatic stress disorder (PTSD). While neurobiological studies have implicated limbic, salience, and prefrontal systems in C-PTSD, mechanistic accounts linking these findings to disturbances in self-organization and treatment-relevant processes remain underdeveloped.Objective: This narrative review develops a hypothesis-generating neurocognitive account of C-PTSD grounded in predictive processing and self-modelling frameworks, with particular emphasis on affective dysregulation and disturbances in self-organization.Method: We synthesize clinical, neurobiological, and theoretical evidence to conceptualize PTSD and C-PTSD along a continuum of regulatory stability, and to advance a conceptual model highlighting the role of insula-mediated self-modelling processes. Within this framework, we examine 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy, as one illustrative intervention that may transiently modulate affective salience, interpersonal trust, and self-referential cognition.Results: The proposed model integrates converging evidence linking insular function to interoception, affective experience, salience processing, and self-referential cognition, and situates disturbances in self-organization as emerging from maladaptive predictive regulation under conditions of prolonged interpersonal adversity. This framework helps reconcile overlapping neurobiological findings across PTSD and C-PTSD while accounting for differences in symptom generalization, relational threat processing, and affective stability.Conclusions: This review delineates a set of testable, mechanistically grounded hypotheses concerning the role of self-modelling processes in C-PTSD. These hypotheses generate specific predictions for future empirical work and inform the design and evaluation of pharmacological and psychotherapeutic interventions that aim to recalibrate affective regulation and self-referential processing in complex trauma presentations.

01 Aug 2026·WATER RESEARCH

Impact of nano zero valent iron dosing on biotransformation and adsorption of 20 biomarkers in sewers

Article

Author: Cen, Xiaotong ; Li, Jiaying ; Prasad, Pritesh ; Ren, Jianan ; Zheng, Min ; Thai, Phong K ; Mueller, Jochen F ; Covaci, Adrian ; Li, Jiuling

Understanding the stability of biomarkers during sewer transport is one of the crucial steps when applying wastewater-based epidemiology (WBE) for assessing consumption or exposure to chemicals. Their stability could be impacted by chemical dosing, a common method used to control the generation of hydrogen sulfide in urban sewer networks. Nano zero valent iron (nZVI) has recently attracted attention due to its effectiveness on sulfide and methane removal. However, the impact of dosing nZVI on the transformation of biomarkers in sewers and the consequent influence on WBE estimation remains unknown. This study investigated the impact of nZVI dosage on adsorption and biotransformation processes of 20 pharmaceutical biomarkers in lab-scale sewer reactors. Dosing nZVI (50 mg Fe/L) effectively inhibited the production of sulfide and changed microbial communities in sewer biofilms. There was no adsorption observed when biomarkers interacted with nZVI only, indicating that adsorption to nZVI dosing was not the main mechanism for biomarker transformation. Meanwhile, the duration and amount of dosing nZVI had no impact on stable biomarkers with less 15% loss (e.g. cotinine, OH-cotinine, benzoylecgonine and acesulfame). In contrast, nZVI dosing affected the transformation of inherently moderately stable biomarkers like methamphetamine, 3,4-methylenedioxymethamphetamine, methylone, carbamazepine, ketamine and atenolol. These findings revealed the complex impacts of nZVI on mediating sewer conditions, biological compositions and in-sewer stability of biomarkers. An evaluation framework was applied to jointly consider the impact of nZVI dosing and hydraulic retention time on biomarker stability, which provides new knowledge for WBE's application in dynamic sewer systems.

488

News (Medical) associated with Methylenedioxymetamfetamine

16 Jun 2026

·www.prnewswire.com

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme VANCOUVER, BC, June 16, 2026 /PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the " Company" or " Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized clinical research organizations. Microdosing refers to taking low, sub-perceptual doses of a psychedelic on a repeated schedule. Common regimens include the Fadiman protocol (one day on, two days off) and the Stamets protocol (four days on, three days off), which build in rest days to limit tolerance. CEO and Co-Founder Dane Stevens said: "Most microdosing relies on dried mushrooms, whose psilocybin content varies widely from batch to batch. Optimi's capsules instead deliver naturally derived psilocybin at a validated, consistent dose, pairing the natural source many researchers prefer with the accurate dosage that controlled research requires. The 1mg and 2mg dosage formats extend Optimi's psilocybin range, which already includes the 5 mg capsule formulation currently prescribed for treatment-resistant depression in Australia." Optimi produces these products start to finish in-house, cultivating and harvesting the mushrooms, generating a full-spectrum mushroom extract as the active pharmaceutical ingredient (API), and formulating, encapsulating, and packaging the finished product for export to clinical research organizations. Every stage is completed on-site Optimi's wholly owned GMP facility in Princeton, British Columbia, Canada, under its Health Canada Drug Establishment License (DEL). Optimi supplies finished psilocybin and MDMA drug products to regulated markets internationally, supporting both patient access and clinical research. Inquiries about product supply for special access programs and clinical trials may be directed to [email protected]. About Optimi Health Corp. Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit or optimi.net. Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the availability, intended use and potential benefits of the Company's 1 mg and 2 mg microdose psilocybin finished drug products, the Company's ability to supply finished psilocybin and MDMA drug products and other psychedelic drug products to qualified, authorized clinical research organizations and regulated markets internationally; the anticipated demand for, benefits of and commercial opportunities associated with the Company's psilocybin product portfolio and supply operations; the Company's ability to maintain applicable licenses, authorizations and regulatory approvals; and the Company's ability to support patient access, special access programs, authorized prescriber programs and clinical research. Forward-looking statements are often identified by words such as "expects," "anticipates," "believes," "intends," "plans," "estimates," "seeks," "may," "will," "would," "could," or similar expressions. Forward-looking statements are based on a number of assumptions and estimates and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time, which are available at and in the Company's continuous disclosure filings available under its SEDAR+ profile at . These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release. SOURCE Optimi Health Corp 21% more press release views with Request a Demo

12 Jun 2026

·allsci.com

Otsuka completes USD 1.2b acquisition of Transcend Therapeutics for PTSD neuroplastogen

Otsuka Pharmaceutical has completed its acquisition of Transcend Therapeutics, with New York-based Transcend now a wholly owned subsidiary of Otsuka America, Inc., the US arm of Japan-based Otsuka Pharmaceutical Co., Ltd. The deal, originally announced in March 2026, positions Otsuka to advance TSND-201 (methylone), a Phase III-stage neuroplastogen for post-traumatic stress disorder, through a therapeutic area where no new FDA-approved treatments have emerged in over two decades. The transaction was structured as a full corporate acquisition, with Otsuka America paying USD 700 million upfront and Transcend shareholders eligible for up to USD 525 million in contingent commercial sales milestone payments, bringing total potential consideration to USD 1.225 billion. No individual milestone tiers were disclosed. Because the deal is a whole-company acquisition rather than a territorial license, Otsuka obtains worldwide, unrestricted rights to Transcend’s entire portfolio across all indications. Closing conditions have now been satisfied. TSND-201 is classified as a rapid-acting neuroplastogen — an agent designed to induce rapid and durable neural plasticity through action on monoamine transporters for serotonin, norepinephrine, and dopamine. Critically, the compound has no activity at the serotonin 5-HT2A receptor, which mediates hallucinogenic effects, distinguishing it from classical psychedelics such as psilocybin and from MDMA-based approaches currently in development. This non-hallucinogenic profile is clinically significant: it may eliminate the need for the extended supervised psychotherapy sessions that characterize psychedelic-assisted therapy models, simplifying administration and potentially broadening patient access. In the Phase II IMPACT-1 trial — a randomized, double-blind, placebo-controlled study enrolling 65 adults with severe PTSD across 16 sites — TSND-201 demonstrated a statistically significant placebo-adjusted improvement in CAPS-5 total severity scores of −9.64 points at Day 64 (p \= 0.011), with statistically significant separation from placebo observed as early as Day 10. Results were published in JAMA Psychiatry. The US FDA granted TSND-201 Breakthrough Therapy Designation in July 2025, and the program subsequently received an FDA Commissioner’s National Priority Voucher. A Phase III trial for PTSD is currently ongoing. For Otsuka, the acquisition consolidates a strategic bet on rapid-acting CNS mechanisms at a time when the psychiatric drug development field is actively seeking alternatives to slow-onset antidepressant and anxiolytic classes. The company has operated in psychiatric and neurological fields since the 1970s and previously expanded its CNS pipeline through the acquisition of Mindset Pharma, which contributed serotonin 5-HT2A agonist discovery technology. TSND-201’s non-hallucinogenic, monoamine-based profile complements rather than overlaps with that existing portfolio, providing differentiated coverage across multiple pharmacological approaches to psychiatric disease. Transcend was founded in 2021 and had raised approximately USD 50 million prior to the transaction. The company is also advancing novel prodrugs of TSND-201, classified as new chemical entities, intended to further optimize the compound’s efficacy, safety, and tolerability profile. A development candidate has been selected and is undergoing non-clinical studies in preparation for an Investigational New Drug application to the FDA — providing Otsuka with potential pipeline optionality beyond the current Phase III program. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 2Clinical ResultAcquisitionPhase 3Breakthrough Therapy

10 Jun 2026

·www.prnewswire.com

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office VANCOUVER, BC, June 10, 2026 /PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the " Company" or " Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial. The shipment comprises psilocybin biomass and finished 5mg psilocybin capsules, supplied to support a planned Phase 2 clinical trial in the United Kingdom. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression (TRD). Optimi intends to announce the trial partner and indication at a later date. The exported product was manufactured at Optimi's GMP facility in Princeton, British Columbia, Canada, and shipped under export authorization issued by Health Canada and import authorization from the UK Home Office. The export follows Optimi's recently announced completion of a GMP production run of its 5mg psilocybin drug product, a portion of which was earmarked to support clinical research in Europe. Optimi cultivated the biomass and produced the finished capsules in-house, extracting the active pharmaceutical ingredient (API) using its proprietary methods, all under its Health Canada Drug Establishment Licence (DEL). The ability to supply both biomass and finished drug product from a single licensed facility positions Optimi as a vertically integrated GMP supplier for regulated psychedelic research and medicine. "This is our first shipment into the United Kingdom, and it is the same psilocybin we already supply to patients in Australia," said Dane Stevens, CEO and Co-Founder of Optimi. "We can serve a commercial market and a clinical trial from the same GMP facility, on our own licence. That is a rare position, and one we have spent years building." Optimi supplies finished psilocybin and MDMA drug products to regulated markets internationally, in support of both patient access and clinical research. Inquiries regarding product for special access programs and clinical trial supply may be directed to [email protected]. About Optimi Health Corp. Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit or optimi.net. Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the planned clinical trial in the United Kingdom, the Company's ability to supply finished psilocybin drug product and biomass as a vertically integrated supplier and the anticipated benefits and commercial opportunities of the Company's psilocybin supply operations for regulated psychedelic research and medicine. Forward-looking statements are often identified by words such as "expects," "anticipates," "believes," "intends," "plans," "may," "will," "would," "could," or similar expressions. Forward-looking statements are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at or in the Company's continuous disclosure filings available under its SEDAR+ profile at . These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release. SOURCE Optimi Health Corp 21% more press release views with Request a Demo

Phase 2

100 Deals associated with Methylenedioxymetamfetamine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Methylenedioxymetamfetamine	-	DB01454

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stress Disorders, Post-Traumatic	NDA/BLA	United States	Lykos Therapeutics, Inc.	13 Dec 2023
Anorexia Nervosa	Phase 2	-	Lykos Therapeutics, Inc.	01 Feb 2026
Binge-Eating Disorder	Phase 2	-	Lykos Therapeutics, Inc.	01 Feb 2026
Alcoholism	Phase 2	-	Awakn Life Sciences, Inc.	05 May 2022
Anxiety Disorders	Phase 2	United States	Lykos Therapeutics, Inc.	14 May 2015
Autistic Disorder	Phase 2	United States	Lykos Therapeutics, Inc.	11 Apr 2014
Liver Injury	Phase 1	United States	Lykos Therapeutics, Inc.	29 Mar 2026
Hyperexplexia Hereditary	Phase 1	United States	Lykos Therapeutics, Inc.	14 Mar 2017
Mood Disorders	Phase 1	Switzerland	Universitätsspital Basel	01 Jun 2001
Substance-Related Disorders	Phase 1	Switzerland	Universitätsspital Basel	01 Jun 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05523401 (Pubmed \| Neuropsychopharmacology)	Phase 1	-	24	2C-B 10mg	bjxfpzadau(ovgnxkzcyz) = Only psilocybin induced 'bad drug effects' and 'anxiety' compared with placebo cfaxhxvypc (eeitjtshwe ) View more	Positive	28 Apr 2026
				MDMA 125mg
NCT04784143 (MPVA6, CTgov)	Phase 2	Stress Disorders, Post-Traumatic	26	Psychotherapy+Midomafetamine (Two Sessions of MDMA-assisted Therapy)	ldfuevunru(pvompykuij) = djbcodqwwc qhljtyznsn (yrkzhullyv, 9.38) View more	-	15 Jul 2025
				Psychotherapy+Midomafetamine (Three Sessions of MDMA-assisted Therapy)	ldfuevunru(pvompykuij) = ukuyvsftuf qhljtyznsn (yrkzhullyv, 13.92) View more
NCT04030169 (CTgov)	Phase 2	Stress Disorders, Post-Traumatic	21	Midomafetamine HCl	inprknduuv(ftrykphnoh) = dhrfqcrdku pqadqmfkim (emekfyzcrh, jbudszlevd - buoddhzygm) View more	-	28 Jan 2025
NCT04714359 (MAPPUSX, CTgov)	Phase 3	Stress Disorders, Post-Traumatic	87	Midomafetamine HCl	mqsrlbigdo(frwswhfyza) = ldrtgrvjxs gccmifgsss (gcunozfuvp, rcqgsrphfw - gunabrgond) View more	-	29 Nov 2024
NCT04053036 (MAT, CTgov)	Early Phase 1	Autism Spectrum Disorder \| Autistic Disorder	22	placebo (Placebo)	xmbjmmawto(vmmwfhqwfs) = bsurqocpgo jadnjxzbrs (fdtjwdcsbi, .7) View more	-	25 Nov 2024
				MDMA (MDMA)	xmbjmmawto(vmmwfhqwfs) = xrcocsiupx jadnjxzbrs (fdtjwdcsbi, .5) View more
ESC2024	Not Applicable	-	-	Recreational drug users	oeefbrpbfx(giiqireyvc) = oabtshxpzw cvxxtqfwxl (ixxpovgmxj )	-	31 Aug 2024
				Non-users	oeefbrpbfx(giiqireyvc) = cfkwjmtpgm cvxxtqfwxl (ixxpovgmxj )
NCT03790618 (ESP, CTgov)	Phase 1	-	36	3,4-Methylenedioxymethamphetamine+methamphetamine (Placebo)	pcvcsejmyl(ggppwsiwns) = ekeqpuytgn nsuqpjwgxd (soctqyblic, 3.22) View more	-	05 Jan 2024
				3,4-Methylenedioxymethamphetamine+methamphetamine (Low Dose MDMA)	pcvcsejmyl(ggppwsiwns) = pmajyatoct nsuqpjwgxd (soctqyblic, 3.14) View more
NCT04077437 (phase 3 \| MAPP2, CTgov)	Phase 3	Stress Disorders, Post-Traumatic	121	Therapy+Midomafetamine (Experimental: MDMA-assisted Psychotherapy)	yyltdrqkcd(stesgpyklm) = xgtyszdogi tmdtiffcbd (ovzzacnltd, bfpwiohbut - mcndqurqle) View more	-	11 Oct 2023
				Placebo (Placebo Comparator: Placebo)	vfxnckkxjf(ftrzotcnnl) = snotoopyry effqxmeaex (qgjeilazdd, iwmhbxtcuf - ygsfgufeco)
NCT01458327 (CTgov)	Phase 2	Stress Disorders, Post-Traumatic	3	3,4-methylenedoxymethamphetamine (MDMA)	wcbnkpbzig(murdyvsphs) = jkvbhiirum giyfcihhpw (vipcxwnyer, 1.53) View more	-	03 Nov 2021
NCT00090064 (CTgov)	Phase 2	Stress Disorders, Post-Traumatic	23	Lactose placebo pill	fvvwowdfvz(njavkhhrxh) = ueatdsorsc pjpdfebcai (vjjlxyxcxs, 20.47) View more	-	25 Oct 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis